Literature DB >> 31161457

Comment on: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Joël Coste1,2, Xavier Bertagna3, Mahmoud Zureik4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31161457     DOI： 10.1007/s40262-019-00779-9

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  1 in total

1.  Authors' Reply to Lechat et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Authors:  Didier Concordet; Peggy Gandia; Jean-Louis Montastruc; Alain Bousquet-Mélou; Peter Lees; Aude A Ferran; Pierre-Louis Toutain
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447
  1 in total
  2 in total

1.  Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Authors:  Didier Concordet; Peggy Gandia; Jean-Louis Montastruc; Alain Bousquet-Mélou; Peter Lees; Aude A Ferran; Pierre-Louis Toutain
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

2.  Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands.

Authors:  Pieter J Glerum; Marc Maliepaard; Vincent de Valk; Joep H G Scholl; Florence P A M van Hunsel; Eugène P van Puijenbroek; David M Burger; Kees Neef
Journal:  Clin Transl Sci       Date:  2020-02-12       Impact factor: 4.689
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.